Synapse

← EJC Paediatric Oncology

Papers in EJC Paediatric Oncology

Page 2 · newest first

  1. Primary Central Nervous System Lymphomas in Children and AdolescentsEJC Paediatric Oncology · 2026
  2. Rare non-Hodgkin lymphomas in childhood and adolescence: From rare to recognized entitiesEJC Paediatric Oncology · 2026
  3. Paediatric nodal marginal zone lymphomaEJC Paediatric Oncology · 2026
  4. High-grade/large B-cell lymphoma with 11q aberration: A distinct molecularly defined entity in contemporary pathobiological classificationsEJC Paediatric Oncology · 2026
  5. [18F]FDG-avid nodal gliomatosis associated with ovarian immature teratoma – The importance of histological confirmationEJC Paediatric Oncology · 2026
  6. Large B-cell lymphoma with IRF4-rearrangement (LBCL-IRF4+) among children, adolescents and young adults (CAYA), a narrative reviewEJC Paediatric Oncology · 2026
  7. Five years of centralized pediatric oncology care in the Netherlands: Evaluation of diagnosis and treatment of children and adolescents with a malignant extracranial germ cell tumorEJC Paediatric Oncology · 2026
  8. Hypercalcaemia associated with Tovorafenib discontinuation in three paediatric patientsEJC Paediatric Oncology · 2026
  9. Experiences of receiving explanations about medical conditions among adolescent children with cancer: A qualitative studyEJC Paediatric Oncology · 2026
  10. Multi-tyrosine kinase inhibitors in paediatric soft tissue sarcoma – A reviewEJC Paediatric Oncology · 2026
  11. Evaluation of the impact of adherence to infection prevention measures on the quality of life in children with hematologic malignanciesEJC Paediatric Oncology · 2026
  12. Characterising childhood cancer survivors in Germany: A retrospective observational study on demographic, clinical, and healthcare utilisation patternsEJC Paediatric Oncology · 2025
  13. Transition needs and preferences identified during peer visits to three European best-practice CAYA cancer Long-Term Follow-Up care centres: An EU-CAYAS-NET projectEJC Paediatric Oncology · 2025
  14. P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastomaEJC Paediatric Oncology · 2025
  15. Recommended phase 2 dose for abemaciclib in combination with irinotecan and temozolomide in pediatric and young adult patients with relapsed/refractory solid tumors: Results from JPCS study (Part A)EJC Paediatric Oncology · 2025
  16. Childhood cancer survival in low- and middle-income countries and the Global South: emerging evidence and critical gaps from a scoping review of observational studiesEJC Paediatric Oncology · 2025
  17. The path towards a population-based childhood cancer registry in the region of Dakar in Senegal: A feasibility study of the Franco-African Paediatric Oncology Group (GFAOP)EJC Paediatric Oncology · 2025
  18. Risk factors for relapse and guidance for follow-up of extracranial immature teratomas in children: A systematic reviewEJC Paediatric Oncology · 2025
  19. A multi-dimensional approach to recognize genetic predisposition in children with acute lymphoblastic leukemiaEJC Paediatric Oncology · 2025
  20. Social interactions and psychosocial development of adolescent and young adult childhood cancer survivors: a scoping review of qualitative researchEJC Paediatric Oncology · 2025
  21. Current insights and future directions in systemic therapies for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) in children and adolescents: a critical review of advancements and challengesEJC Paediatric Oncology · 2025
  22. Developing patient reported outcome measures for children with cancer: A current perspectiveEJC Paediatric Oncology · 2025
  23. Local therapy for rhabdomyosarcoma of the bladder and/or prostate without nodal or metastatic spread during the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 studyEJC Paediatric Oncology · 2025
  24. Familial risks and incidence rates for childhood nervous system tumors in SwedenEJC Paediatric Oncology · 2025
  25. Multicentre evaluation of the management of children with high risk medulloblastoma: Real world performance of the SJMB03 and COG-99701 protocolsEJC Paediatric Oncology · 2025
  26. Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trialEJC Paediatric Oncology · 2025
  27. Hearing your child is diagnosed with leukemia: A qualitative study into parents’ perspectivesEJC Paediatric Oncology · 2025
  28. HOW ARE YOU FEELING TODAY? – Gaps and opportunities in capturing patient reported outcomes (PROs) in Pediatric Cancer CareEJC Paediatric Oncology · 2025
  29. From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescentsEJC Paediatric Oncology · 2025
  30. Proton beam therapy in paediatric radiation oncology: Defining the limitations, uncertainties and optimisation of treatment plansEJC Paediatric Oncology · 2025
  31. Dexamethasone/vincristine pulses significantly reduce administered doses of 6MP/MTX during maintenance therapy in childhood acute lymphoblastic leukemiaEJC Paediatric Oncology · 2025
  32. SSPedi and SPARK: Promise for the future of electronic patient reported outcomes in pediatric oncologyEJC Paediatric Oncology · 2025
  33. Impact of COVID-19 pandemic on childhood cancer incidence and stage in France – A national registry-based studyEJC Paediatric Oncology · 2025
  34. A structured approach for data collection and visualization of the International Childhood Cancer Core OutcomesEJC Paediatric Oncology · 2025
  35. Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closureEJC Paediatric Oncology · 2025
  36. Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcomaEJC Paediatric Oncology · 2025
  37. Cognitive and adaptive functioning outcomes after cancer diagnosis in early childhood: A systematic reviewEJC Paediatric Oncology · 2025
  38. Dabrafenib and trametinib either in combination or as monotherapy in pediatric patients harboring BRAF alterations in gliomas or other rare tumors: Findings from a managed access programEJC Paediatric Oncology · 2025
  39. Diagnosis of a congenital nodule labelled pigmented epithelioid melanocytoma unconfirmed by recent molecular biology toolsEJC Paediatric Oncology · 2025
  40. Assessing patient-reported outcomes (PROs) in paediatric oncology research: Which PRO would a pro pick, if a pro was picking PROs?EJC Paediatric Oncology · 2025
  41. Transcriptional regulation of genes by MYCN in PAX3::FOXO1-positive rhabdomyosarcomas and their roles in cell cycle progressionEJC Paediatric Oncology · 2025
  42. European standard clinical practice recommendations for children and adolescents with Rhabdomyosarcoma a joint EpSSG, CWS and ERN PaedCan projectEJC Paediatric Oncology · 2025
  43. European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescenceEJC Paediatric Oncology · 2025
  44. Immunotherapy for paediatric diffuse large B-cell lymphoma: A review of current clinical trials and future directionsEJC Paediatric Oncology · 2025
  45. An overview of the European standard clinical practice recommendations for choroid plexus tumoursEJC Paediatric Oncology · 2025
  46. Curing using the minimal – Strategies for treatment reduction in childhood acute lymphoblastic leukemiaEJC Paediatric Oncology · 2025
  47. Therapeutic drug monitoring in the treatment of childhood acute lymphoblastic leukemia – A practical guidelineEJC Paediatric Oncology · 2025
  48. Screening for childhood cancer: Several devils in the detailsEJC Paediatric Oncology · 2025
  49. IGH rearrangements in Down syndrome acute lymphoblastic leukemiaEJC Paediatric Oncology · 2025
  50. Non-invasive wearable devices in paediatric cancer care: Advancing personalized medicine, addressing challenges and shaping the futureEJC Paediatric Oncology · 2025